Literature DB >> 33962485

Transfusion support during childbirth for a woman with anti-U and the RHD*weak D type 4.0 allele.

Q Yin1, K Srivastava2, D G Brust3, W A Flegel4.   

Abstract

D- red blood cells (RBCs), always in short supply, and Rh immune globulin (RhIG) are not needed for patient care if D+ RBCs can safely be transfused. According to a recent work group recommendation, patients with the RHD*weak D type 4.0 allele can be considered D+. We report an African American woman who presented for delivery at the end of the third trimester, at which time anti-U and a serologic weak D phenotype were recognized, requiring U-, D- RBC units. We obtained 3 U- RBC units, including 1 D- unit. Later, the RHD*weak D type 4.0 allele was determined by RHD genotyping, only 6 days before delivery. The patient had an uneventful vaginal delivery of a D+ baby. No transfusion was needed for mother or baby. In this case, a pregnant woman with the RHD*weak D type 4.0 allele can safely be managed as D+, relaxing the unnecessary D- restriction for the limited U- RBC supply. The procured U-, D- RBC unit was frozen with 14 days of shelf-life remaining. To conserve D- RBC units, not limited to U-, for patients with a definite need, we recommend molecular analysis of a serologic weak D phenotype before a transfusion becomes imminent. The best time to resolve a serologic weak D phenotype with RHD genotyping is early in a pregnancy. Immunohematology 2021;37:1-4 . D– red blood cells (RBCs), always in short supply, and Rh immune globulin (RhIG) are not needed for patient care if D+ RBCs can safely be transfused. According to a recent work group recommendation, patients with the RHD*weak D type 4.0 allele can be considered D+. We report an African American woman who presented for delivery at the end of the third trimester, at which time anti-U and a serologic weak D phenotype were recognized, requiring U–, D– RBC units. We obtained 3 U– RBC units, including 1 D– unit. Later, the RHD*weak D type 4.0 allele was determined by RHD genotyping, only 6 days before delivery. The patient had an uneventful vaginal delivery of a D+ baby. No transfusion was needed for mother or baby. In this case, a pregnant woman with the RHD*weak D type 4.0 allele can safely be managed as D+, relaxing the unnecessary D– restriction for the limited U– RBC supply. The procured U–, D– RBC unit was frozen with 14 days of shelf-life remaining. To conserve D– RBC units, not limited to U–, for patients with a definite need, we recommend molecular analysis of a serologic weak D phenotype before a transfusion becomes imminent. The best time to resolve a serologic weak D phenotype with RHD genotyping is early in a pregnancy. Immunohematology 2021;37:1–4 .

Entities:  

Year:  2021        PMID: 33962485      PMCID: PMC8108908          DOI: 10.21307/immunohematology-2021-001

Source DB:  PubMed          Journal:  Immunohematology        ISSN: 0894-203X


  17 in total

1.  RHD gene deletion occurred in the Rhesus box.

Authors:  F F Wagner; W A Flegel
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

2.  Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D.

Authors:  Kevin J Pirelli; Bradley C Pietz; Susan T Johnson; Holly L Pinder; Daniel B Bellissimo
Journal:  Prenat Diagn       Date:  2010-12       Impact factor: 3.050

3.  Genetic mechanisms of Rhesus box variation.

Authors:  Franz F Wagner; Joann M Moulds; Willy A Flegel
Journal:  Transfusion       Date:  2005-03       Impact factor: 3.157

4.  A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes.

Authors:  Willy A Flegel; Thierry Peyrard; Jacques Chiaroni; Christophe Tournamille; Déborah Jamet; France Pirenne
Journal:  Blood Transfus       Date:  2018-05-03       Impact factor: 3.443

5.  Experience with RHD*weak D type 4.0 in the USA.

Authors:  Connie M Westhoff; Sandra Nance; Christine Lomas-Francis; Margaret Keller; Stella T Chou
Journal:  Blood Transfus       Date:  2018-07-06       Impact factor: 3.443

6.  Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists.

Authors:  S Gerald Sandler; Susan D Roseff; Ronald E Domen; Beth Shaz; Jerome L Gottschall
Journal:  Arch Pathol Lab Med       Date:  2014-05       Impact factor: 5.534

7.  Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype.

Authors:  Seema Kacker; Ralph Vassallo; Margaret A Keller; Connie M Westhoff; Kevin D Frick; S Gerald Sandler; Aaron A R Tobian
Journal:  Transfusion       Date:  2015-03-21       Impact factor: 3.157

8.  Relevance and costs of RHD genotyping in women with a weak D phenotype.

Authors:  L Laget; C Izard; E Durieux-Roussel; J Gouvitsos; I Dettori; J Chiaroni; V Ferrera-Tourenc
Journal:  Transfus Clin Biol       Date:  2018-06-01       Impact factor: 1.406

9.  It's time to phase out "serologic weak D phenotype" and resolve D types with RHD genotyping including weak D type 4.

Authors:  Willy A Flegel; Gregory A Denomme; John T Queenan; Susan T Johnson; Margaret A Keller; Connie M Westhoff; Louis M Katz; Meghan Delaney; Ralph R Vassallo; Clayton D Simon; S Gerald Sandler
Journal:  Transfusion       Date:  2020-03-12       Impact factor: 3.337

10.  RHD allele distribution in Africans of Mali.

Authors:  Franz F Wagner; Joann M Moulds; Anatole Tounkara; Bourema Kouriba; Willy A Flegel
Journal:  BMC Genet       Date:  2003-09-24       Impact factor: 2.797

View more
  2 in total

1.  What constitutes the most cautious approach for a pregnant person with weak D type 4.0?

Authors:  Willy Albert Flegel; Melanie Bodnar; Gwen Clarke; Judith Hannon; Lani Lieberman
Journal:  CMAJ       Date:  2021-06-14       Impact factor: 8.262

2.  Proceed with care: the "uncommon" serologic weak D phenotypes.

Authors:  Willy Albert Flegel
Journal:  Blood Transfus       Date:  2021-07       Impact factor: 3.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.